Glenmark Pharmecuaticals’ novel chemical entity “Revamilast” has initiated Phase II B human dose range finding trial globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.
The Phase II studies going to be carried out will help establish the efficacy and safety of the molecule and will also provide dose range finding data for Revamilast.
Glenmark Pharmecuaticals is research driven globally integrated pharmaceuticals company headquartered in Mumbai. It is leading player in the discovery of new molecules both NCEs (New chemical entity) and NBEs (New biological entity).
